Summary: The treatment of severe asthma is a challenge for the primary care physician, especially when it is difficult to gain long-term control of the disease. A commonly used group of drugs in such cases are systemic glucocorticoids. However, this form of treatment is often associated with very serious side effects and is sometimes poorly tolerated by patients. Detailed knowledge of the mechanisms of asthma development has allowed new drugs to be obtained, in the form of monoclonal antibodies, eg omalizumab (anti-IgE antibodies) and mepolizumab (anti-IL-5 antibodies), which is characterized by clinical efficacy (reduction in the number and severity of exacerbations and the frequency of hospitalizations due to exacerbations, and the need for oral and inhaled glucocorticoids) without serious side effects. Due to this, it is worth considering referring a patient suffering from severe uncontrolled asthma to centers conducting biological therapies within NFZ (National Health Fund) therapeutic programs instead of administering another course of oral glucocorticoids or using them chronically, the more so since these antibodies are recommended by a group of international experts of the Global Initiative for Asthma in the GINA report 2018, as well as by the Polish Society of Allergology.